BUZZ-Piper Sandler upgrades Sight Sciences on strong business prospects
I'm PortAI, I can summarize articles.
Piper Sandler has upgraded Sight Sciencesto "overweight" from "neutral," highlighting strong prospects for its TearCare and surgical glaucoma businesses. The price target is raised to $9 from $5, indicating over 20% upside. Sight Sciences shares rose 5.2% to $7.87 premarket. While the long-term outlook for TearCare is positive, caution is advised as the company seeks insurance reimbursement. Currently, 3 of 7 brokerages rate SGHT as "buy" or higher, with a median price target of $8.55. Over the past year, the stock has declined by 5.7%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments